A long-established medical cannabis clinic and research organisation in Canada has begun recruitment for a study of patient outcomes from personalised medical cannabis treatment plans.
Santé Cannabis was established in 2014 and has supported 20,000 patients since it was founded. Canada’s first independently accredited cannabis Contract Research Organization (CRO), the organisation holds four Cannabis Research Licenses, facilitates clinical trials and observational studies, and is a recognized McGill University teaching site.
Santé Cannabis is leading recruitment of 3,000 patients for a new study that will explore patient outcomes over a 12-month period; including benefits, safety risks, substitution of medication and cost analysis. The study will run over 3 years.
Medical Director and Co-founder of Santé Cannabis, Dr. Michael Dworkind – who is also an Associate Professor in Family Medicine at McGill University – says while medical cannabis has been legally accessible in Canada for almost a quarter of a century, many clinical questions remain unanswered about its therapeutic use.
“This is such an important initiative to prioritize patients’ needs in the age of cannabis legalization,” he said.
The study will include outcomes from the use of newer products such as capsules, tablets and sublingual products, and cannabinoid formulations such as cannabinol (CBN) and cannabigerol (CBG).
Read the full article at Hemp Gazette.
